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Introduction: Nowadays Enterococcus faecium has become one of the most emerging and challenging nosocomial
pathogens. The aim of this study was to determine risk factors in haematology patients who are at risk of an
Enterococcus faecium bloodstream infection (BSI) and should be considered for pre-emptive glycopeptide
treatment. With these identified risk factors a prediction model can be developed for clinical use.
Methods: Retrospectively clinical and microbiological data in 33 patients with an E. faecium BSI were compared to
66 control patients during a 5-year period at the haematology ward. Multivariate logistic regression was used to
explore the independent risk factors and a prediction model was developed to determine the risk of an E. faecium BSI.
Results: E. faecium BSIs were found to be associated with high mortality rates. Independent risk factors for E. faecium
BSI were colonization with E. faecium 30 days prior to blood culture (OR 5.71; CI 1.7-18.7), combination of neutropenia
and abdominal focus (4.37; 1.4-13.4), age > 58 years (4.01; 1.3-12.5), hospital stay prior to blood culture > 14 days
(3.55; 0.98-12.9) and CRP (C-reactive protein) level >125 mg/L (4.37; 1.1-10.2).
Conclusion: Using data from this study, risk stratification for the development of an E. faecium BSI in patients with
haematological malignancies is possible. Pre-emptive treatment should be considered in those patients who are at
high risk. Using a prediction model as designed in this study, antibiotic stewardship in terms of prudent use of
glycopeptides can be improved and might be helpful in controlling further spread of VRE (vancomycin resistant
enterococci).
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Enterococcus faecium has become one of the most im-
portant, emerging and challenging nosocomial patho-
gens [1]. It is a difficult to treat pathogen due to
intrinsic resistances to cephalosporins, aminoglycosides
(low-level resistance), clindamycin and trimethoprim-
sulfamethoxazole [2]. Moreover, it has the ability to
easily acquire virulence or antibiotic resistance genes
trough transfer of plasmids, chromosomal exchange or
mutation [3].* Correspondence: x.w.zhou@umcg.nl
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reproduction in any medium, provided the orDue to the resistance of multiple antibiotics, the treat-
ment of choice in serious E. faecium infections is glyco-
peptides. However, prudent use of vancomycin is needed
as it is associated with an increased risk for VRE infec-
tion and colonization [4]. The emergence of VRE has
been reported one to two decades ago in the United
States [5]; more recently alarming reports are now com-
ing from many countries in Europe [6].
Several studies have pointed out the existence of two
subpopulations of E. faecium: commensal/community-
associated (CA) strains and clinical or hospital associated
(HA) strains, whereas the latter is also referred as the
clonal complex 17 (CC-17) group [7]. These HA/CC-17
strains are associated with ampicillin resistance; the risetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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coccus species are especially due to these strains [8].
A predominant part of the nosocomial E. faecium
bloodstream infections concerns patients with haemato-
logic malignances who are immunocompromised by their
severe disease and intensive treatment. Whereas it often is
debated whether to treat E. faecium as a real pathogen,
several studies have shown high morbidity and mortality
rates for enterococcal bacteremia (mortality rates ranging
from 25% to 51%), especially in immunocompromised pa-
tients [9-11]. Moreover, the mortality rates increases with
inappropriate antimicrobial therapy [12].
After coagulase negative staphylococci (CoNS), strep-
tococci and Escherichia coli (E. coli), E. faecium is
the most predominant species isolated among blood
cultures at the haematology unit of our hospital.
Compared to other pathogens such as CoNS, E. coli,
Pseudomonas aeruginosa (P. aeruginosa) and strepto-
cocci which remained stable or decreased, E. faecium
increased for the periods 1998–2006 (3.1%) and 2007–
2010 (12.8%) which is 4.1 times more.
Since patients with haematologic malignancies are
highly prone to infection, prophylactic antibiotics are
used to prevent and reduce any risk of infection. In our
haematology ward penicillin and ciprofloxacin or co-
trimoxazol or colistine or tobramycin (orally) are used
depending on the resistance pattern of bacteria found in
surveillance cultures. In case a haematology patient pre-
sents with neutropenic fever or other clinical signs of
infection, blood cultures are taken and empirical broad-
spectrum antibiotic treatment is started, which is
piperacillin-tazobactam.
Glycopeptides are not recommended as a standard
part of the initial antibiotic regimen for fever and neu-
tropenia. Moreover, as noted earlier, for the further pre-
vention and control of VRE it is necessary to control the
use of glycopeptide antibiotics. At this moment, glyco-
peptides are only added in case of a positive blood cul-
ture with E. faecium or oxacillin resistant CoNS.
However blood culture results and their susceptibilities
are only available after one or more days after blood
samples are drawn.
Therefore the aim of this study is to identify possible
risk factors in those haematology patients who are at high
risk of E. faecium bloodstream infection in order to de-
velop a prediction model for clinical stringent use. This
can be useful in the decision of pre-emptive therapy with
glycopeptides together with the initial empirical antibiotic
treatment at the moment a blood culture is taken.
Methods
Study design and population
The University Medical Center Groningen (UMCG) is a
1300-bed tertiary center and has a 27-bed haematologyward. This ward has four 4 patient rooms, one double
room and nine private rooms. Patients were identified
by a search of the laboratory electronic database for all
blood cultures between September 2005 and September
2010 from the haematology ward. In this period a total
of 1086 patients were admitted to the haematology ward
of whom 672 blood cultures were taken. (Figure 1) Case
patients were identified by a search for all blood cultures
positive for E. faecium. Of each patient with an E.
faecium blood culture, the first positive blood culture
was selected: a total of 33 patients with E. faecium blood
cultures were identified. For the main purpose of our
study, (an algorithm to decide whether or not to add gly-
copeptides to the initial empirical antibiotic therapy at
the moment a blood culture is taken) we choose to use a
selection of all the patients of which a blood culture was
taken (positive as well as negative), except those with
E. faecium blood culture (n = 672-33 = 639). After all,
this whole group had the same grounds to obtain a blood
culture at the (retrospective) moment the blood culture
was drawn. This would also be the case in prospective sit-
uations where this algorithm could be applied on. A total
of 66 control patients were randomly selected: first a
patient was randomly selected; subsequently a blood cul-
ture was randomly selected. Patients were not matched
for age or sex.
Data collection
Patient data were gathered by reviewing hospital elec-
tronic records and stored hard-copy records. The date the
blood culture was taken was chosen as day 0 and from
that point all data were reviewed all data retrospectively.
Clinical data collected included information of under-
lying disease, admission status, co-morbidities, neutro-
penia, C-reactive protein (CRP) levels, fever and signs
of organ failure prior to blood culture. Microbio-
logical data collected included clinical source of infec-
tion, information about E. faecium colonization and
antibiotic use 30 days prior to positive blood culture.
If a patient had diarrhea, records were also reviewed
for Clostridium difficile. Antibiotic susceptibility pat-
terns, presence of polymicrobial bacteremia and positive
galactomannan tests were gathered. Antibiotic treatment
with vancomycin or teicoplanin for E. faecium bacteremia
was evaluated. Outcomes were measured by need of ICU
admission and mortality at 7 and 30 days after blood
culture.
Clinical notifications and definitions
During the retrospective study period, blood cultures were
drawn for neutropenic fever or other clinical signs for in-
fection. Fever was defined as temperature >38.5°C or >
38°C for 24 hours was a reason for further examin-
ation. An absolute neutrophil count below 0.5 × 109/L
Figure 1 Patients at the haematology ward of the UMCG during the period September 2005-September 2010: Thirty-three of the
patients with positive blood cultures (672) had an E. faecium blood culture (~5%).
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ing definitions were used: renal failure was defined as
creatinin >176 μmol/L, hepatic failure as bilirubin
>43 mmol/L and pulmonary failure as bilateral lung infil-
trates or signs of acute respiratory distress syndrome
(ARDS). These definitions were according to guidelines
used for defining organ failure in severe sepsis [13].
Polymicrobial infection was defined as a micro-organism
other than E. faecium within ± 7 days of the blood culture.
For the controls it was defined as an additional micro-
organism within ± 7 days of a positive blood culture. In
this definition less pathogenic micro-organisms such as
CoNS, Corynebacteriae, Micrococcus spp. and Bacillus
spp. as an additional micro-organism were excluded.Infection prevention regimen haematology ward
At the haematology ward of our hospital, selective de-
contamination of the digestive tract (SDD) is performed
in patients with an (expected) reversible neutropenia or
increased risk of infection. The implementation is as fol-
lows: surveillance cultures from faeces, throat and urine
at admission day, then once a week only faeces and
throat cultures during the duration of neutropenia. Peni-
cillin (to prevent streptococcal sepsis) and ciprofloxacin
or cotrimoxazol or colistine or tobramycin (orally) are
used as prophylactic antibiotics depending on the resist-
ance pattern of surveillance cultures. Amphoterin B,
nystatin or fluconazole are given orally as antifungal
therapy. The choice of empirical antibiotic therapy is
piperacillin-tazobactam.
Screening for E. faecium in this period was done on
BME(G) agar plates. This contained Meropenem 64 mg/L,
Oxacillin 10 mg/L, Amphotericin-B 20 mg/L and esculin.
Hereby we screened for ampicillin resistant E. faecium
(HA E. faecium). From January 2007 these agar plates also
contained gentamicin 128 mg/L since there was anincrease of high level gentamicin resistant E. faecium in
our hospital from that time period.
Identification and susceptibility testing
Blood cultures were performed using the BACTEC sys-
tem (Becton Dickinson™). Further determination and
susceptibility testing were performed for gram positive
streptococci that were catalase negative and PYR posi-
tive. As for E. faecium surveillance cultures, only col-
onies that grew on the BMEG plates with black borders
were further determined. Species were identified using
the VITEK®2 System (BioMérieux™) or API20 Strep
System (BioMérieux™). Subsequently antimicrobial sus-
ceptibility testing was performed using the VITEK®2 Sys-
tem or disk diffusion tests respectively.
Statistical analyses
Statistical analyses were performed using SPSS for Win-
dows, rel 18.0. Univariate analyses were performed using
the Fisher’s exact or Chi-square methods for categorical
variables. The Student’s t-test or Mann–Whitney U-test
was used for the continuous variables. Results with a
p-value of ≤0.05 were considered to be statistically
significant. All p-values are two-tailed. Significant vari-
ables were used in the multivariate logistic regression.
Deriving prediction model from a nested case–control
design
To overcome the overestimation of risks because of
overrepresentation of cases, we choose to perform a
nested case–control design where the cases represent
5% and controls 95% of the whole population (Figure 1).
Therefore the following factor to the intercept of the
logistic regression model is added: c = ln (q0/ (1-q0)),
whereas q0 is the true prevalence of the diseases in the
population. With this correction the risk of an indi-
vidual to get the disease can be estimated by the formula
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β0 is the intercept from the linear regression equation, β1/
βk is the regression coefficient derived from the multivari-
ate logistic regression and X1/Xk is the value of the pre-
dictor. In this study, q0 is the prevalence of patients with
an E. faecium blood culture. Since we were only interested
in those patients of whom a blood culture is drawn, c = ln
(0.05/ (1–0.05)) = −2.94. Controls should be a random se-
lection representative of the population [14] which is the
case since we randomly selected the 66 control patients.Results
Patients
A total of 99 patients were evaluated: 33 cases (E.
faecium) and 66 controls. Characteristics of the 66 con-
trols showed the following blood culture results: E. coli
(n = 4), Streptococcus viridans (n = 2), CoNS (n = 4),
Corynebacterium spp. (n = 1) and no growths (n = 55).
Comparisons of the demographic and clinical data are
presented in Table 1. There were no significant differ-
ences between type or status of disease. Patients with
E. faecium bacteremia were associated with higher age
and longer hospitalization days prior to blood culture as
well as one year before admission. They were also associ-
ated with severe and longer duration of neutropenia, lon-
ger duration of fever and higher CRP levels at time of
blood culture withdrawal. Penicillin and quinolones as a
part of the SDD regimen and piperacillin-tazobactam as
empirical broad-spectrum antibiotics were the most fre-
quently used antibiotics; however this did not differ be-
tween the two groups. Only “other” antibiotics were more
frequently given in the E. faecium group. This was mainly
colistine, a polymixin antibiotic, though colistine use alone
was not significant.Microbes
From the 33 cases, fourteen patients (42.4%) had a single
blood culture, nineteen (57.6%) had more than one
blood culture and 11 (33.3%) had more than two blood
cultures. All E. faecium blood isolates were resistant to
amoxicillin. No VRE strains were identified in this study.
High-level gentamicin resistance (HLGR) was found in
19 (57.6%) of the 33 E. faecium blood isolates. Three of
the 19 patients with HLGR E. faecium also had low level
gentamicin resistant E. faecium in their blood cultures
(multiple blood cultures).
Comparisons of the microbial data are presented in
Table 2. Polymicrobial infections were found in 9.1%
of the cases compared to 1 (1.5%) in the control group
(p= 0.107). Pathogens isolated were Clostridium perfringens,
Pseudomonas aeruginosa, and Streptococcus species. Three
case patients (9.1%) had a positive Galactomannan com-
pared to 2 (3.0%) in the control group (p = 0.330).An abdominal focus was found to be associated with E.
faecium bacteremia (p = 0.003) of which diarrhea appeared
to be most distinct variable. Only one patient with an E.
faecium BSI had a positive Clostridium difficile toxin test
(no C. difficile in stool culture) at time of diarrhea. This
was two days prior to the positive blood culture, together
with a positive E. faecium faeces culture, though this pa-
tient was already colonized with E. faecium for several
weeks.
Patients with E. faecium BSI were more often detected
to be colonized with E. faecium prior to blood culture
(p = <0.001). A total of twenty-one patients (63.6%) were
colonized with E. faecium prior to the positive blood
culture with a median of 1 (range 0–8), compared to
24.2% in the control group with a median of 0 (range
0–6). Twelve patients (36.4%) were not found to be colo-
nized with the surveillance cultures. However, nine of
these twelve patients had a blood culture with low level
gentamicin resistant E. faecium. Seven of these twelve
patients (58.3%), had a positive faeces culture with E.
faecium after all within 30 days after positive blood
culture; five with high level gentamicin resistant E.
faecium, two with low level gentamicin resistant E.
faecium. The majority of the patients (69.7%) were
still colonized up to 30 days after the first positive
blood culture. This includes both patients that were
already colonized and patients who had a positive
culture with E. faecium within 30 days after their
positive blood culture.
Outcomes and treatment
Both groups had an equal antibiotic treatment for
piperacillin-tazobactam as well as for glycopeptide treat-
ment at time of blood culture withdrawal. (Table 3) Pa-
tients with an E. faecium BSI were more often admitted
to the ICU after the positive blood culture. Reasons for
ICU admissions were predominantly sepsis, mostly with
an abdominal focus (abdominal sepsis). The 7-day mor-
tality as well as the 30-day mortality were significantly
higher in patients with E. faecium BSI compared to the
control group (30.3% vs 4.5%; p = 0.001 and 39.4% vs
10.6%; p = 0.001 respectively). All 10 patients with E.
faecium BSI that died within 7 days after their last posi-
tive culture were diagnosed with sepsis or severe infec-
tion, six of them (60%) had an clear abdominal focus
(abdominal sepsis). Another three patients died after
30 days, one diagnosed with a septic shock, the other
two patients had multiple diagnoses.
More detailed data considering antibiotic treatment in
patients with an E. faecium BSI including mortality rates
are presented in Table 4. Only 4 patients (12.1%) re-
ceived glycopeptide treatment at time of blood culture
withdrawal. Three of them had an empirical treatment
and one received treatment because of an earlier proven
Table 1 Comparison of demographic and clinical characteristics of cases (E. faecium) and controls
Demographics Cases (n = 33) Controls (n = 66) p-value
Male gender 18 (68.2%) 45 (54.5%) 0.184
Age, mean ± SD, years 58.0 ± 11.3 52.2 ± 9.1 0.008
Type of malignancy: a 0.378
Leukaemia (AML, MDS, ALL) for chemotherapy 19 (57.6%) 28 (42.6%)
Leukemia for allogeneic stem cell transplantation 2 (6.1%) 2 (3.0%)
Lymphoma’s, Kahler, CLL and others undergoing autologous stem cell transplantation 6 (18.2%) 17 (25.8%)
Lympfhoma’s, Kahler, CLL not undergoing autologous stem cell transplantation 6 (18.2%) 19 (28.8%)
Status of disease:
Remission 9 (27.3%) 11 (16.7%) 0.215
Not in remission b 24 (72.7%) 55 (83.3%) 0.215
Relapse 7 (21.2%) 14 (21.2%) 1.000
Reason for admission: 0.476
Infection 4 (12.1%) 13 (19.7%)
Chemotherapy 21(63.6%) 34 (51.5%)
Stem cell transplantation c 8 (24.2%) 19 (28.8%)
Length of hospital stay:
Length in days prior to positive blood culture, median (range) 21 (2–52) 13.5 (1–84) 0.007
Length in days 1 year before admission, median (range) 43 (6–131) 24 (1–133) 0.018
Signs of organ failure: d
Renal (creatinine > 176 μmol/L) 2 (6.1%) 3 (4.5%) 0.746
Hepatic (bilirubin >34 mmol/L) 2 (6.1%) 0 (0.0%) 0.109
Lung (bilateral lung infiltrates) 4 (12.1%) 10 (15.2%) 0.769
Days of fever, median (range) d 2 (0–7) 0 (0–6) 0.001
Neutropenia:
Neutropenia <0.1 × 109/L e 20 (60.6%) 19 (28.8%) 0.002
Neutropenia <0.5 × 109/L e 28 (84.8%) 28 (42.4%) <0.001
Neutropenia <2.0 × 109/L e 29 (87.9%) 39 (59.1%) 0.004
Duration of neutropenia <0.5 × 109/L prior to blood culture, median (range) 8.0 (0–27) 0.0 (0–26) <0.001
CRP (C-reactive protein in mg/L):
Levels 7 days prior to blood culture, median (range) 26 (3–263) 47 (5–347) 0.07
Levels at time of blood culture, median (range) 188 (7–288) 108 (3–426) 0.006
At time of blood culture CRP >125 mg/L 23 (69.7%) 24 (36.4%) 0.002
Antibiotic therapy at time of blood culture and/or 30 days before:
Penicillins 24 (72.7%) 40 (60.6%) 0.234
Cotrimoxazole 12 (36.4%) 18 (27.3%) 0.353
Quinolones 25 (75.8%) 51 (77.3%) 0.866
Cephalosporins 6 (18.2%) 4 (6.1%) 0.079
Carbapenems 6 (18.2%) 5 (7.6%) 0.113
Others f 19 (57.6%) 16 (24.2%) 0.001
aAML acute myeloid leukaemia, MDS myelodysplastic syndrome, ALL acute lymphoblastic leukaemia, CLL chronic lymphoblastic leukaemia. bIncluding patients
partially in remission. cAllogeneic as well as autologous stem cell transplantation. dAt the day of blood culture till 7 days prior to blood culture. eAt the day of
blood culture withdrawal fcolistin, tetracyclin, macrolides, aminoglycosides, metronidazole.
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(57.6%) received glycopeptide treatment. Of these 19
cases, four were empirically treated upfront because ofseptic profile, two cases because of a CoNS infection
and 13 cases recommended by the medical microbiolo-
gist because of suspected or proven E. faecium blood
Table 2 Comparison of the microbiological characteristics of cases (E. faecium) and controls
Cases (n = 33) Controls (n = 66) p-value
Colonization with E. faecium a
7 days prior to blood culture 13 (39.4%) 10 (15.2%) 0.007
30 days prior to blood culture 19 (57.6%) 14 (21.2%) <0.001
90 days prior to blood culture 21 (63.6%) 16 (24.2%) <0.001
Number of faeces cultures with E. faecium 30 days prior to blood culture, median (range) 1 (0–8) 0 (0–6) <0.001
Type of blood culture
Polymicrobial b 3 (9.1%) 1 (1.5%) 0.107
Galactomannan 3 (9.1%) 2 (3.0%) 0.330
Clinical source of infection
Abdominal focus: abdominal pain and/or diarrhea 25 (75.8%) 29 (43.9%) 0.003
Abdominal pain 9 (27.3%) 11 (16.7%) 0.215
Diarrhea 23 (69.7%) 26 (39.4%) 0.004
Mucositis 13 (39.4%) 18 (27.3%) 0.220
Lungs
Coughing and/or sputum 8 (24.2%) 15 (22.7%) 0.866
Radiological proof of pneumonia or lung infiltrates 4 (12.1%) 14 (21.2%) 0.269
Ear Nose Throat 1 (3.0%) 2 (3.0%) 1.000
Skin 7 (21.2%) 19 (28.8%) 0.419
Urinary infection 1 (3.0%) 9 (13.6%) 0.158
aIn faeces culture, part of the SDD regimen. bWithin ± 7 days, less pathogenic micro-organisms (coagulase-negative staphylococci, corynebacteria, micrococcus
spp. and bacillus spp.) are excluded.
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treatment for their infection after 24 hours.
Additional statistical analyses were performed on pa-
tients with an E. faecium BSI (cases) to determine add-
itional risk factors for mortality. Only the numbers of
blood cultures were found to be statistically significant
for mortality at 7 days, with significant trend effect in
case of more positive blood cultures. (Additional file 1)
None of the other demographic, clinical or microbio-
logic factors listed in Tables 1 and 2 (e.g. neutropenia,
mucositis, glycopeptide treatment) were found to be
additional risk factors.
Multivariable regression analysis and prediction modeling
Variables included in the multivariate regression analyses
are shown in Table 5. Independent risk factors for anTable 3 Comparison of outcome and antibiotic treatment of c
Piperacillin-tazobactam treatment at time blood culture is drawn and/or 30 d
Vancomycin/teicoplanin treatment at time of blood culture withdrawal




*After last positive blood culture with E. faecium.E. faecium BSI are colonization with E. faecium 30 days
prior to blood culture (OR 5.71; CI 1.7-18.7), combin-
ation of neutropenia and abdominal focus (4.37; 1.4-13.4),
age > 58 years (4.01; 1.3-12.5), hospital stay prior to blood
culture > 14 days (3.55; 0.98-12.9) and CRP (C-reactive
protein) level >125 mg/L (4.37; 1.1-10.2).
Subsequently these independent risk factors were used
in order to develop the prediction model. A subset of
this prediction model is shown in Table 6. Hereby the
formula eβ0+c+ β1X1+…βkXk / 1 + e β0+c+ β1X1+…βkXk was
used, whereas β was deduced from the multivariate re-
gression analysis as shown in Table 5. Since five variables
were tested and used in this model, a total of 32 out-
comes are possible. If a patient has all the five variables
at the moment of blood culture withdrawal, the risk of
an E. faecium BSI is 47.5%. If a patient has none of theases (E. faecium) and controls
Cases (n = 33) Controls (n = 66) p-value
ays before 22 (66.7%) 42 (63.6%) 0.766
4 (12.1%) 8 (12.1%) 1.000
5 (15.2%) 1 (1.5%) 0.015
10 (30.3%) 3 (4.5%) 0.001
13 (39.4%) 7 (10.6%) 0.001
Table 4 Antibiotic treatment with vancomycin or teicoplanin in patients with E. faecium BSI, including mortality rates
(n = 33)
Vancomycine/teicoplanin treatment cases (n = 33)
Yes No
Empirical Mortality Therapeutic Mortality Mortality
At time of blood culture withdrawal
3 2/3 1* 0 29 11/29
(9.1%) (66.7%) (3%) (0%) (87.9%) (37.9%)
After 24 hrs
4 3/4 13 + 2* 5/15 14 5/14
(12.1%) (75%) (45.5%) (33.3%) (42.4%) (35.7%)
*Because of coagulase negative staphylococci.
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making the clinician can fill in the variables; 0 for a
negative and 1 for a positive score and thereby deduce
the risk of E. faecium BSI. (All 32 variables and probabil-
ities are available in an Additional file 1).
Discussion
Nowadays E. faecium has become an emerging and chal-
lenging pathogen in hospitals and even more has
replaced E. faecalis as the predominant enterococcus
species [8]. The increase of E. faecium BSIs in our study
are in line with the numbers of a recent EARSS
(European Antimicrobial Resistance Surveillance Sys-
tem) study, in which E. faecium increased most signifi-
cant in BSIs compared to other major pathogens [15].
All E. faecium strains from the blood cultures in our
study belonged to the HA/CC-17 strains. They were all
amoxicillin (ampicillin) resistant and insertion sequence
16 (IS16) positive, which is a marker for these strains
[16]. HA/CC-17 strains seem to be successful in acquir-
ing accessory virulence and antibiotic genes and there-
fore might set the stage for VRE [17]. In vancomycin
resistant E. faecium infections, adequate treatment of
serious infections becomes limited. Although some novel
antimicrobials such as linezolid and daptomycin have
been developed, these also have their limitations; more-
over resistance to these antimicrobials has already been
described [18].
In line with previous studies prior colonization with
HA E. faecium showed to be an independent risk factor
for E. faecium BSI [19,20]. This study showed that the
majority of patients (63.6%) were first colonized prior toTable 5 Multivariate logistic regression analyses: risk factors
Variables tested
A. Colonization with E. faecium 30 days prior to blood culture
B. Neutropenia and abdominal focus*
C. Age > 58 years
D. Days of admission prior to blood culture > 14 days
E. CRP >125 mg/L
*Abdominal pain and/or diarrhea. B = regression coefficient. P p-value. OR Odds ratithe development of E. faecium BSI; moreover it seemed
to be the most important/significant independent risk
factor for E. faecium BSI in our study. It is important to
keep in mind that multiple swabs might be needed to
detect the majority of carriers [21] and E. faecium can
persist for a long period [22] which is also seen in
our study. Environmental contamination and person-to-
person spread are factors contributing to the acquisition
of E. faecium [23,24]. Enterococcus spp. are quite ten-
acious and may survive for more than 4 months under
dry conditions [25]. Therefore standard hygiene (e.g.
hand hygiene) and appropriate infection-control mea-
sures (e.g. risk surface disinfection) are essential.
Neutropenia and abdominal focus (diarrhea and/or ab-
dominal pain) were also associated with E. faecium BSI.
Because these variables seem to be related to each other,
as they individually excluded each other in regression ana-
lysis, the two variables were combined. The extensive
chemo- and transplantation therapy the patients receive is
often associated with neutropenia and diarrhea [26]. In
case of severe neutropenia or chemotherapy induced diar-
rhea which can be seen as injury of the mucosal barrier, E.
faecium has the opportunity to enter the bloodstream.
Subsequently we expected mucositis, which relates
more to the oral toxicity of chemotherapy, to be an asso-
ciated variable. Kuehnert et al. showed that the risk of
VRE BSI increased with increasingly severe mucositis
[27]. In contrast, Worth et al. didn’t find mucositis to be
associated with E. faecium infection; however it hadn’t a
well-validated mucositis severity index [28]. Perhaps a
more validated mucositis stratification would have
shown other results in our study.associated with an E. faecium BSI (n = 33)
B p OR [95% CI]
1.742 0.004 5.71 [1.7–18.7]
1.474 0.010 4.37 [1.4–13.4]
1.390 0.017 4.01 [1.3–12.5]
1.267 0.054 3.56 [0.98–12.9]
1.216 0.032 4.37 [1.1–10.2]
o. 95% CI 95% confidence interval.
Table 6 Prediction model to determine the risk of E.
faecium BSI (subset)
A B C D E Probability
1 1 1 1 1 47.5
1 1 1 1 0 21.2
1 1 1 0 1 20.3
1 1 0 1 1 18.4
1 0 1 1 1 17.2
0 1 1 1 1 13.7
0 0 0 0 0 0.08
For this prediction model the formula eβ0+c+ β1X1+…βkXk / 1 + e β0+c+ β1X1+…βkXk
was used, whereas β was deduced from the multivariate regression analysis as
shown in Table 5. 0 variable absent, 1 variable present A Colonization with E.
faecium 30 days prior to blood culture B Neutropenia and abdominal focus
(diarrhea or abdominal pain) C Age over 58 years D Days of admission prior to
blood culture more than 14 days E CRP >125 mg/L.
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found to be significant. However, they individually ex-
cluded each other in the regression analysis. Therefore
we chose to include CRP level in our model as it is a
more objective parameter. Especially in these haematol-
ogy patients, fever can be aspecifically related to for ex-
ample drug fever or inflammation like mucositis.
Not many studies have identified age to be an inde-
pendent risk factor. However the majority of the patients
with E. faecium infections in the studies are at higher
age (50–70 years) and these studies included a more spe-
cific control group [11,29,30] whereas we choose a ran-
dom selection representative for the total population of
the haematology ward during the study period.
Since E. faecium is considered to be a nosocomial
pathogen, a prolonged hospital length of stay as a pre-
dictor in E. faecium bacteremia is as we expected. For
VRE as a multi-resistant pathogen it is clear it is associ-
ated with a longer hospital length of stay. Though also
for vancomycin-susceptible (VSE), but ampicillin resist-
ant E. faecium (ARE) as in our study, this association
had been shown [31,32].
Another risk factor often associated with E. faecium
infection is previous antibiotic use [30]. Moreover, num-
bers of enterococci in SDD increases since they are not
covered [33]. We haven’t found a strong association be-
tween antibiotic use and an E. faecium BSI, since the
majority of both patient groups received SDD.
Additional analysis between patients with and without
an E. faecium BSI did not result in additional risk factors
for mortality besides the total number of positive E.
faecium blood cultures. However numbers were often too
small to perform adequate statistical analyses between the
two groups.
This study has some limitations. Firstly, the data was
retrospectively gathered. Although both stored-hard
copy and electronic records were reviewed, for certainclinical parameters precise monitoring was difficult.
Secondly, this is a single-centre study whereas local epi-
demiological variables and infection prevention mea-
sures must be considered. Thirtly, from January 2007
surveillance cultures were screened for meropenem and
high level gentamicin resistant E. faecium. The reason
for this was an increase in E. faecium of which the major
part was high level gentamicin resistant in our hospital
from that time period. An unknown number of E.
faecium of gentamicin susceptible surveillance cultures
have been missed during this period. However, we still
detected some gentamicin low level resistant E. faecium
(5/200 patients ~5%) from that time period. From
February 2011 we use 2 mg/L gentamicin in our BMEG
screening agars instead of 128 mg/L. Hereby we see an
increase of ~30% due to low level gentamicin E. faecium
in the haematology ward for the period February 2011 –
July 2013. However, there seems to be a shift again from
2012, whereas gentamicin high level E. faecium, ac-
counts for up to 80% of the HA E. faecium both in
screening cultures as well as in blood cultures for the
period February 2012 – July 2013. This should be taken
into account considering results of E. faecium coloniza-
tion in our study. It is difficult to assess the implication
of this limitation on the prediction model with respect
to the odds ratio. Moreover, patients can have several E.
faecium strains in their surveillance cultures as well as
in blood cultures. Finally the majority of our control
group had blood cultures with ‘no growths’. This might
have several reasons, for example patients could have
had fever due to the malignancy or drug fever or inflam-
mation because of mucositis. It could also partially be
explained by the fact patients received SDD. One can
state that these patients had a lower degree of illness,
compared to patients with an E. faecium blood culture.
However, retrospective circumstances for both groups
were equal. Both groups had the same grounds to obtain
a blood culture; neutropenic fever or other clinical signs
of infection. Also for the purpose of the study, a predic-
tion model in order to decide whether or not add glyco-
peptide to the empirical antibiotic treatment at the
moment a blood culture is drawn, we choose to select
this group of patients as controls.
In conclusion this study demonstrated that coloniza-
tion with HA E. faecium 30 days prior to blood culture,
combination of neutropenia and abdominal focus, age >
58 years, hospital stay prior to blood culture > 14 days
and CRP level >125 mg/L are independent risk factors
for E. faecium BSI. In agreement with previous studies,
this study showed that E. faecium infections can cause
severe infections and are associated with high mortality
rates in patients with haematologic malignancies [10,34].
Thereby risk stratification becomes necessary in those
haematology patients at high risk. Using a prediction
Zhou et al. Antimicrobial Resistance and Infection Control 2013, 2:24 Page 9 of 10
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antibiotic stewardship in terms of prudent use of glyco-
peptides becomes possible. Together with infection con-
trol measures this might be helpful controlling further
increase of VRE. The prediction model in this study is
based on one specific haematology ward, though it
would be worthwhile to verify this prediction model in a
prospective multicenter study.
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